Impact of ivermectin on illness and disability associated with onchocerciasis

James M. Tielsch, Arlyne Beeche

Research output: Contribution to journalArticle

Abstract

The Onchocerciasis Control Program (OCP), one of the most successful vertical disease control programs in the history of public health, came to an end in 2003 with devolvement of responsibilities for control program activities passed to the countries affected. Fortunately, 15 years ago the Mectizan® Distribution Program (MDP) was founded to provide a complementary approach to controlling the disabling consequences of this parasitic infection. With over 250 million doses of ivermectin distributed over the past 15 years, the MDP is well on its way to both solidifying the progress made by the OCP and extending program reach well beyond the boundaries of the OCP. Through the extensive clinical testing protocols implemented in a variety of countries in Africa, ivermectin has been proven to be a safe and highly effective treatment for onchocerciasis. Regular distribution to populations living in endemic areas has demonstrated significant reductions in blinding ocular complications, transmission, and disability caused by onchocercal skin disease. As yet undocumented, are the likely significant impact regular population dosing with ivermectin has on intestinal helminth infections, lymphatic filariasis, and human scabies infection. While there are significant barriers to continued program success, focussed attention on expanding and improving community-directed ivermectin distribution is likely to lead to further progress against this resilient infection.

Original languageEnglish (US)
JournalTropical Medicine and International Health
Volume9
Issue number4
DOIs
StatePublished - Apr 2004

Fingerprint

Onchocerciasis
Ivermectin
Infection
Filarial Elephantiasis
Scabies
Parasitic Diseases
Helminths
Clinical Protocols
Skin Diseases
Public Health
History
Demography
Population

Keywords

  • Disability
  • Ivermectin
  • Mectizan
  • Onchocerciasis

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases
  • Parasitology
  • Immunology

Cite this

Impact of ivermectin on illness and disability associated with onchocerciasis. / Tielsch, James M.; Beeche, Arlyne.

In: Tropical Medicine and International Health, Vol. 9, No. 4, 04.2004.

Research output: Contribution to journalArticle

@article{dc6573b6f41740b2a919701a630937f1,
title = "Impact of ivermectin on illness and disability associated with onchocerciasis",
abstract = "The Onchocerciasis Control Program (OCP), one of the most successful vertical disease control programs in the history of public health, came to an end in 2003 with devolvement of responsibilities for control program activities passed to the countries affected. Fortunately, 15 years ago the Mectizan{\circledR} Distribution Program (MDP) was founded to provide a complementary approach to controlling the disabling consequences of this parasitic infection. With over 250 million doses of ivermectin distributed over the past 15 years, the MDP is well on its way to both solidifying the progress made by the OCP and extending program reach well beyond the boundaries of the OCP. Through the extensive clinical testing protocols implemented in a variety of countries in Africa, ivermectin has been proven to be a safe and highly effective treatment for onchocerciasis. Regular distribution to populations living in endemic areas has demonstrated significant reductions in blinding ocular complications, transmission, and disability caused by onchocercal skin disease. As yet undocumented, are the likely significant impact regular population dosing with ivermectin has on intestinal helminth infections, lymphatic filariasis, and human scabies infection. While there are significant barriers to continued program success, focussed attention on expanding and improving community-directed ivermectin distribution is likely to lead to further progress against this resilient infection.",
keywords = "Disability, Ivermectin, Mectizan, Onchocerciasis",
author = "Tielsch, {James M.} and Arlyne Beeche",
year = "2004",
month = "4",
doi = "10.1111/j.1365-3156.2004.01213.x",
language = "English (US)",
volume = "9",
journal = "Tropical Medicine and International Health",
issn = "1360-2276",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Impact of ivermectin on illness and disability associated with onchocerciasis

AU - Tielsch, James M.

AU - Beeche, Arlyne

PY - 2004/4

Y1 - 2004/4

N2 - The Onchocerciasis Control Program (OCP), one of the most successful vertical disease control programs in the history of public health, came to an end in 2003 with devolvement of responsibilities for control program activities passed to the countries affected. Fortunately, 15 years ago the Mectizan® Distribution Program (MDP) was founded to provide a complementary approach to controlling the disabling consequences of this parasitic infection. With over 250 million doses of ivermectin distributed over the past 15 years, the MDP is well on its way to both solidifying the progress made by the OCP and extending program reach well beyond the boundaries of the OCP. Through the extensive clinical testing protocols implemented in a variety of countries in Africa, ivermectin has been proven to be a safe and highly effective treatment for onchocerciasis. Regular distribution to populations living in endemic areas has demonstrated significant reductions in blinding ocular complications, transmission, and disability caused by onchocercal skin disease. As yet undocumented, are the likely significant impact regular population dosing with ivermectin has on intestinal helminth infections, lymphatic filariasis, and human scabies infection. While there are significant barriers to continued program success, focussed attention on expanding and improving community-directed ivermectin distribution is likely to lead to further progress against this resilient infection.

AB - The Onchocerciasis Control Program (OCP), one of the most successful vertical disease control programs in the history of public health, came to an end in 2003 with devolvement of responsibilities for control program activities passed to the countries affected. Fortunately, 15 years ago the Mectizan® Distribution Program (MDP) was founded to provide a complementary approach to controlling the disabling consequences of this parasitic infection. With over 250 million doses of ivermectin distributed over the past 15 years, the MDP is well on its way to both solidifying the progress made by the OCP and extending program reach well beyond the boundaries of the OCP. Through the extensive clinical testing protocols implemented in a variety of countries in Africa, ivermectin has been proven to be a safe and highly effective treatment for onchocerciasis. Regular distribution to populations living in endemic areas has demonstrated significant reductions in blinding ocular complications, transmission, and disability caused by onchocercal skin disease. As yet undocumented, are the likely significant impact regular population dosing with ivermectin has on intestinal helminth infections, lymphatic filariasis, and human scabies infection. While there are significant barriers to continued program success, focussed attention on expanding and improving community-directed ivermectin distribution is likely to lead to further progress against this resilient infection.

KW - Disability

KW - Ivermectin

KW - Mectizan

KW - Onchocerciasis

UR - http://www.scopus.com/inward/record.url?scp=2342652216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342652216&partnerID=8YFLogxK

U2 - 10.1111/j.1365-3156.2004.01213.x

DO - 10.1111/j.1365-3156.2004.01213.x

M3 - Article

C2 - 15078278

AN - SCOPUS:2342652216

VL - 9

JO - Tropical Medicine and International Health

JF - Tropical Medicine and International Health

SN - 1360-2276

IS - 4

ER -